| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 06/14/2006 | CN1788006A Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| 06/14/2006 | CN1787838A Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 06/14/2006 | CN1787837A Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 06/14/2006 | CN1787835A Human lymphocyte vaccine adjuvant |
| 06/14/2006 | CN1787827A A novel polyherbal preparation for the prevention of atherosclerosis and hyperlipidemia |
| 06/14/2006 | CN1787823A 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 06/14/2006 | CN1787820A Composition for improving cognition and memory |
| 06/14/2006 | CN1787817A 免疫抑制剂化合物及组合物 Immunosuppressant compounds and compositions |
| 06/14/2006 | CN1787741A Methods and compositions for the prevention and treatment of sepsis |
| 06/13/2006 | US7060697 Immunosuppressant compounds and compositions |
| 06/13/2006 | US7060260 Water-soluble silk proteins in compositions for skin care, hair care or hair coloring |
| 06/13/2006 | US7060109 Hair dyeing agents containing indigo derivatives |
| 06/13/2006 | CA2433288C Process for making amlodipine maleate |
| 06/08/2006 | WO2005092069A3 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
| 06/08/2006 | WO2005053601A3 Methods of generating stem cells and embryonic bodies carrying disease-causing mutations and methods of using same for studying genetic disorders |
| 06/08/2006 | WO2005042795A3 Plasma polymerization of atomically modified surfaces |
| 06/08/2006 | WO2005041900A3 Polyamine polymers |
| 06/08/2006 | WO2005037219A3 Disinfecting teat care compositions |
| 06/08/2006 | WO2005027833A3 Compound and method for treating androgen-independent prostate cancer |
| 06/08/2006 | WO2005023191A3 Rage-related methods and compositions for treating glomerular injury |
| 06/08/2006 | WO2005020906A3 Intranasal opioid compositions |
| 06/08/2006 | WO2005007106A3 Compositions of a cyclooxygenase-2 selective inhibitor and a non-nmda glutamate modulator for the treatment of central nervous system damage |
| 06/08/2006 | WO2005002527A3 Sirt1 modulation of adipogenesis and adipose function |
| 06/08/2006 | WO2004084820A9 Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
| 06/08/2006 | WO2004073653A3 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
| 06/08/2006 | WO2004014303A3 Method of applying hyaluronic acid to implant or graft to enhance lubricity and cellular density |
| 06/08/2006 | US20060122262 Use of equol for treating androgen mediated diseases |
| 06/08/2006 | US20060122200 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies |
| 06/08/2006 | US20060122183 Synergistic; side effect reduction; melanomas; toxicity; 2,5-Dimethoxythiobenzoic Acid N-methylhydrazine; anticancer |
| 06/08/2006 | US20060122173 Il-8 receptor antagonists |
| 06/08/2006 | US20060122153 Antineoplastic ether lipid compounds with modifications at the sn-2 carbon |
| 06/08/2006 | US20060122117 Method of treating retinopathies and disorders associated with blood vessel loss |
| 06/08/2006 | US20060121480 Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 06/08/2006 | US20060121128 Increasing cytosolic calcium levels in airway epithelial cell by contacting purinergic (P2X) receptors on cell with zinc chloride; cystic fibrosis, asthma, allergies, polycystic kidney disease and salt-sensitive hypertension syndromes, diabetes; drug screening; nasal spray |
| 06/08/2006 | US20060120996 Vaccine immunotherapy for immune suppressed patients |
| 06/08/2006 | US20060120969 Inhalers used in the treatment of diabetes by delivering insulin by way of systemic dose delivery |
| 06/08/2006 | US20060117497 Azo dye for hair; thickener is anionic amphiphilic polymer |
| 06/07/2006 | EP1666481A2 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors |
| 06/07/2006 | EP1666092A2 Drug combination comprising a fatty acid and a uridine compound. |
| 06/07/2006 | EP1666034A1 Pharmaceutical combination comprising a biguanide |
| 06/07/2006 | EP1666029A1 Pressurised metered dose inhalers (MDI) |
| 06/07/2006 | EP1666023A2 Improvements in and relating to carrier particles for use in dry powder inhalers |
| 06/07/2006 | EP1664774A2 A rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method |
| 06/07/2006 | EP1664117A2 Immunogen |
| 06/07/2006 | EP1664033A2 9,10-alpha,alpha-oh-taxane analogs and methods for production the reof |
| 06/07/2006 | EP1664011A2 Ophthalmic compositions for treating ocular hypertension |
| 06/07/2006 | EP1663299A2 Methods for preventing neurological events |
| 06/07/2006 | EP1663276A2 Compounds that modulate neuronal growth and their uses |
| 06/07/2006 | EP1663262A2 Bowman-birk inhibitor compositions for treatment of muscular atrophy and degenerative muscle disease |
| 06/07/2006 | EP1663255A2 Withanamide and withanolide compositions and method of use thereof |
| 06/07/2006 | EP1663254A2 Anti-inflamatory phosphonate conjugates |
| 06/07/2006 | EP1663239A2 Potassium channel mediated delivery of agents through the blood-brain barrier |
| 06/07/2006 | EP1663204A2 C-kit modulators and methods of use |
| 06/07/2006 | EP1663194A2 Method of treating cancer with hdac inhibitors |
| 06/07/2006 | EP1663186A2 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound |
| 06/07/2006 | EP1663175A2 Oral drug delivery system |
| 06/07/2006 | EP1663159A2 Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
| 06/07/2006 | EP1663157A2 Stabilized formulations of phosphatidylserine |
| 06/07/2006 | EP1663156A2 Chronotherapeutic dosage forms |
| 06/07/2006 | EP1663142A2 Compositons and methods for topical administration |
| 06/07/2006 | EP1663128A2 Novel therapeutic extracts and molecules for degenerative conditions |
| 06/07/2006 | EP1663114A2 Therapeutic immunization of hiv-infected individuals |
| 06/07/2006 | EP1663113A2 Substituted sulfonamides |
| 06/07/2006 | EP1663112A2 Intranasal opioid compositions |
| 06/07/2006 | EP1663111A2 Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides |
| 06/07/2006 | EP1663110A2 Uses of interferons with altered spatial structure |
| 06/07/2006 | EP1663109A2 Ultrasonic concentration of drug delivery capsules |
| 06/07/2006 | EP1663108A2 Echogenic coatings with overcoat |
| 06/07/2006 | EP1663103A2 Compositions of botanical extracts for cancer therapy |
| 06/07/2006 | EP1662876A2 Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| 06/07/2006 | EP1662875A2 Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders |
| 06/07/2006 | EP1563066A4 Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein |
| 06/07/2006 | EP1558597A4 Continuous process for the production of optically pure (s)-beta hydroxy-gamma-butyrolactone |
| 06/07/2006 | CN1784901A System and method for processing a digital television signal having multiple content ratings each one associated with different content rating system |
| 06/07/2006 | CN1784408A 8-substituted-6,7,8,9-tetrahy9dropyrimido (1,2-a) pyrimidin-4-one derivatives |
| 06/07/2006 | CN1784406A Purification and crystalline forms of zaleplon |
| 06/07/2006 | CN1784396A P38 inhibitors and methods of use thereof |
| 06/07/2006 | CN1784387A Benzimidazole derivatives |
| 06/07/2006 | CN1784236A Androgen receptor modulators and methods of use thereof |
| 06/07/2006 | CN1784226A Benzimidazoles, compositions containing such compounds and methods of use |
| 06/07/2006 | CN1784212A Oral care methods and products |
| 06/07/2006 | CN1781927A Mevalonic acid derivative |
| 06/07/2006 | CN1781911A Intermediate for producing novel pyrazine derivatives |
| 06/07/2006 | CN1781511A Application of plant extract for preparing medicine to cure bone absorption increment diseases and composition thereof |
| 06/07/2006 | CN1781483A Treatment of diabetes with thiazolidinedione and metformin |
| 06/07/2006 | CN1258587C Liquid soap containing trichlorophenylurea and its preparing method |
| 06/07/2006 | CN1258526C Substituted beta-diketones and their use |
| 06/06/2006 | US7057049 Mitogen-activated protein kinase inhibitors |
| 06/06/2006 | US7056946 antitumor taxane containing a carboante group at c-10 position, benzoyoxy at c-2 position and hydroxy at c-7 position in the ring (c3o-c6-c6-c8) |
| 06/06/2006 | US7056936 Synergistic combination |
| 06/06/2006 | US7056529 Vesicle comprises ATP and phospholipid; fusion proteins |
| 06/06/2006 | US7056494 Method of treating a systemic disease |
| 06/06/2006 | CA2410196C Apparatus and process for in situ manufacture of essence from living, uncut plants |
| 06/06/2006 | CA2327723C Bicyclic hydroxamic acid derivatives |
| 06/06/2006 | CA2282585C Pyrazine compounds |
| 06/01/2006 | WO2005048936A3 Modulators of dimethylarginine dimethylaminohydrolase and methods of use thereof |
| 06/01/2006 | WO2005032495A3 Gene expression profiles and methods of use |
| 06/01/2006 | WO2004091550A3 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives |
| 06/01/2006 | WO2004080407A3 New serotonin modulating compounds and uses therefor |
| 06/01/2006 | WO2004066932A3 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |